MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, P. T.
Right arrow Articles by Lentz, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, P. T.
Right arrow Articles by Lentz, T. L.

Distribution of alpha-bungarotoxin binding sites over residues 173-204 of the alpha subunit of the acetylcholine receptor

PT Wilson, E Hawrot and TL Lentz

Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510.

The binding of alpha-bungarotoxin to several synthetic peptides comprising different segments of the region 173-204 of the alpha subunit of the Torpedo acetylcholine receptor was investigated to further localize the neurotoxin-binding site on the primary sequence. When tested in a solid phase microwell assay system, a 32-amino acid peptide corresponding to residues 173-204 (32-mer) bound 125I-alpha- bungarotoxin with the same affinity (4.2 x 10(-8) M as determined from IC50 values) as the isolated alpha subunit (4.6 x 10(-8) M). The relative affinities of other antagonists (alpha-cobratoxin, d- tubocurarine) maintained the same rank order in this assay system as has been demonstrated with the intact receptor. Agonists competed with binding of toxin at millimolar concentrations but lost all rank order of potency. These findings demonstrate that peptide 173-204 contains many of the antagonist-binding determinants present on denatured alpha subunit but has lost specificity of agonist binding. To further localize the toxin-binding site, alpha-bungarotoxin binding to seven shorter peptides corresponding to portions of the 32-mer was investigated. 125I-alpha-Bungarotoxin bound to alpha subunit peptides 179-192, 181-198, 185-196, 186-196, and 193-204, but not to alpha subunit peptides 173-180 and 194-204. In a second assay, all of the peptides competed with binding of 125I-acetylcholine receptor to immobilized alpha-bungarotoxin. The apparent affinity was highest for the 173-204 32-mer (1.4 x 10(-7) M) and lowest for peptides 173-180 and 194-204 (greater than 10(-4) M). The affinity of the other peptides was intermediate (approximately 10(-5) M) and about 100-fold less than that of the 32-mer. The affinity of alpha-bungarotoxin was 3.5 x 10(-10) M, of isolated, native acetylcholine receptor, 3.2 x 10(-9) M, and of isolated denatured subunit, 1.2 x 10(-8) M, with this assay. The retention of some toxin-binding capacity by the shorter peptides indicates toxin-binding determinants are distributed over the entire length of the 32-mer. The determinants with higher affinity are located in the central region of the 32-mer between residues 179 and 196.

Volume 34, Issue 5, pp. 643-650, 11/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
I. U. Willcockson, A. Hong, R. P. Whisenant, J. B. Edwards, H. Wang, H. K. Sarkar, and S. E. Pedersen
Orientation of d-Tubocurarine in the Muscle Nicotinic Acetylcholine Receptor-binding Site
J. Biol. Chem., October 25, 2002; 277(44): 42249 - 42258.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zeng and E. Hawrot
NMR-based Binding Screen and Structural Analysis of the Complex Formed between alpha -Cobratoxin and an 18-Mer Cognate Peptide Derived from the alpha 1 Subunit of the Nicotinic Acetylcholine Receptor from Torpedo californica
J. Biol. Chem., September 27, 2002; 277(40): 37439 - 37445.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Yao, J. Wang, N. Viroonchatapan, A. Samson, J. Chill, E. Rothe, J. Anglister, and Z.-Z. Wang
Yeast Expression and NMR Analysis of the Extracellular Domain of Muscle Nicotinic Acetylcholine Receptor alpha Subunit
J. Biol. Chem., April 5, 2002; 277(15): 12613 - 12621.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Mitra, C. P. Wanamaker, and W. N. Green
Rearrangement of Nicotinic Receptor {alpha} Subunits during Formation of the Ligand Binding Sites
J. Neurosci., May 1, 2001; 21(9): 3000 - 3008.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. L. Donnelly-Roberts, P. S. Puttfarcken, T. A. Kuntzweiler, C. A. Briggs, D. J. Anderson, J. E. Campbell, M. Piattoni-Kaplan, D. G. Mckenna, J. T. Wasicak, M. W. Holladay, et al.
ABT-594 [(R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine]: A Novel, Orally Effective Analgesic Acting via Neuronal Nicotinic Acetylcholine Receptors: I. In Vitro Characterization
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 777 - 786.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
Z.-Z. Wang, S. F. Hardy, and Z. W. Hall
Assembly of the Nicotinic Acetylcholine Receptor. THE FIRST TRANSMEMBRANE DOMAINS OF TRUNCATED alpha AND delta SUBUNITS ARE REQUIRED FOR HETERODIMER FORMATION IN VIVO
J. Biol. Chem., November 1, 1996; 271(44): 27575 - 27584.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zeng, L. Moise, M. A. Grant, and E. Hawrot
The Solution Structure of the Complex Formed between alpha -Bungarotoxin and an 18-mer Cognate Peptide Derived from the alpha 1 Subunit of the Nicotinic Acetylcholine Receptor from Torpedo californica
J. Biol. Chem., June 15, 2001; 276(25): 22930 - 22940.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics